Eliem Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 7.76 million compared to USD 10.55 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.4 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.46 USD | -5.45% | -0.90% | +184.44% |
12/06 | Eliem Therapeutics, Inc. Appoints Aoife Brennan as Chief Executive Officer | CI |
12/06 | Eliem Therapeutics, Inc. Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+184.44% | 23Cr | |
+16.44% | 12TCr | |
+20.12% | 12TCr | |
+21.22% | 2.66TCr | |
-23.35% | 1.99TCr | |
-17.47% | 1.63TCr | |
-45.95% | 1.55TCr | |
-18.86% | 1.55TCr | |
+61.75% | 1.48TCr | |
+3.35% | 1.37TCr |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Eliem Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022